Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Claire J. Houston"'
Autor:
Ryan Brown, Caoifa Dougan, Peter Ferris, Rebecca Delaney, Claire J. Houston, Aoife Rodgers, Damian G. Downey, Marcus A. Mall, Bronwen Connolly, Donna Small, Sinéad Weldon, Clifford C. Taggart
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Secretory leukocyte protease inhibitor (SLPI) is an important cationic protein involved in innate airway immunity and highly expressed in mucosal secretions, shown to target and inhibit neutrophil elastase (NE), cathepsin G and trypsin activity to li
Externí odkaz:
https://doaj.org/article/438d37d1f0ab439ab6b29c4beb7f6c88
Publikováno v:
Expert Review of Respiratory Medicine. 14:889-903
Cystic Fibrosis pulmonary exacerbations are critical events in the lives of people with CF that have deleterious effects on lung function, quality of life, and life expectancy. There are significant unmet needs in the management of exacerbations. We
Autor:
Daniel F. McAuley, Joseph C. Kidney, Claire J Houston, Michael C. McKelvey, Dermot Linden, Damian G Downey, Shannice Creane, Declan Doherty, Clifford C. Taggart, Karen Keown, Ryan Brown, Sinéad Weldon
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 6379, p 6379 (2020)
International Journal of Molecular Sciences
Keown, K, Brown, R, Doherty, D F, Houston, C, McKelvey, M C, Creane, S, Linden, D, McAuley, D F, Kidney, J C, Weldon, S, Downey, D G & Taggart, C C 2020, ' Airway Inflammation and Host Responses in the Era of CFTR Modulators ', International journal of molecular sciences, vol. 21, no. 17 . https://doi.org/10.3390/ijms21176379
International Journal of Molecular Sciences
Keown, K, Brown, R, Doherty, D F, Houston, C, McKelvey, M C, Creane, S, Linden, D, McAuley, D F, Kidney, J C, Weldon, S, Downey, D G & Taggart, C C 2020, ' Airway Inflammation and Host Responses in the Era of CFTR Modulators ', International journal of molecular sciences, vol. 21, no. 17 . https://doi.org/10.3390/ijms21176379
The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in disease management, as these small molecules directly target the upstre